Skip to main content

Table 4 Summary of FDA EUA engineering mAbs

From: A critical overview of current progress for COVID-19: development of vaccines, antiviralĀ drugs, and therapeutic antibodies

Antibody

Fc Variants

Binding Affinity

Effector Function

USPTO application

Status of patent

FcĪ³RI

FcĪ³RIIa

FcĪ³RIIIa

FcRn

Xevudy (Sotrovimab)

M428L/

N434S

N.D

ā€‰+ā€‰

[196]

ā€‰+ā€‰

[196]

ā€‰+ā€‰

[205]

ā€¢Enhanced ADCC

ā€¢Enhanced ADCP

ā€¢Enhanced IgG half life

11/124,620

Patented

Evusheld (Cilgavimabā€‰+ā€‰Tixagevimab)

L234F/

L235E/

P331S

ā€‰āˆ’ā€‰

[244]

ā€‰āˆ’ā€‰

[205]

N.D

N.D

ā€¢Reduced ADCC

ā€¢Reduced CDC

ā€¢Enhanced IgG half life

16/159,451

Patented

M252Y/

S254T/

T256E

ā€‰āˆ’ā€‰/ā€‰+ā€‰

[245]

ā€‰āˆ’ā€‰

[245]

ā€‰āˆ’ā€‰

[245]

ā€‰+ā€‰

[205, 246]

13/133,845

Patented

Etesevimab

L234A/

L235A

ā€‰āˆ’ā€‰

[205, 247]

ā€‰āˆ’ā€‰

[247]

N.D

ā€‰+ā€‰

[205]

ā€¢Reduced ADCC

ā€¢Reduced CDC

ā€¢Enhanced IgG half life

15/210,464

Abandoned

  1. Binding affinity of Fc engineered antibodies were compared to wild type antibodies of IgG. Abbreviations: ADCP, antibody-dependent cellular phagocytosis; ADCC, antibody-dependent cell cytotoxicity; CDC, complement-dependent cytotoxicity. -/ā€‰+ā€‰: no change; -: reduction;ā€‰+ā€‰: enhancement; ND: no data